US Generics, ANDA / 505(b)(2), EU / UK / Japan / Australia Generics, Complex & Specialty Formulations Leadership
Formulations (Regulated Markets)
Executive Search
65+ Regulated-Markets Placements — with an average 92 Days time-to-placement and a 12-month candidate guarantee.
65+
Regulated-Markets Placements
92 Days
Avg. Time-to-Placement
90%
Offer Acceptance Rate
12 Months
Candidate Guarantee
Specialisation withinPharmaceuticals & Biotechnology·Innovating for Better Health
Formulations-regulated-markets — the US-generics, EU-generics, UK, Japan, Australia, Canada, South Africa, Brazil, and GCC formulations export business — is India's single largest pharma export tranche and one of the country's most successful global industry positions. Indian pharma operators collectively supply 40%+ of US generic-prescription volume and comparable shares in multiple EU markets. The ecosystem spans large-cap listed pharma majors with material US-generics businesses, mid-cap listed generics specialists, complex-generics and specialty-formulations specialists (listed pharma majors' specialty-and-complex-generics arms, listed biopharma-and-complex-generics operators, and India operations of global complex-generics majors), 505(b)(2) and differentiated-formulations specialists, and PE-backed export-only formulations operators. Leadership here requires fluency in USFDA, UK-MHRA, EMA, PMDA, TGA, WHO-GMP, and country-specific regulatory architecture (ANDA, DMF, CEP, MA, 505(b)(2) NDA), multi-plant regulated-markets manufacturing rhythm (Schedule M, FDA-21-CFR-Part-211, EU-GMP, PIC/S), global-customer-and-wholesaler channel architecture, complex-and-injectable-and-inhalation-and-transdermal formulation stewardship, and the specific Paragraph-IV patent-challenge and first-to-file architecture that defines US-generics economics.
Is This Your Situation?
If any of these sound familiar, you're speaking to the right practice.
→Listed large-cap pharma major running US subsidiary succession — confidential search with promoter and global-leadership alignment across US-generics operating credibility, USFDA-compliance-and-wholesaler-channel stewardship, and Paragraph-IV-and-first-to-file architecture fluency.
→Listed pharma operator scaling its complex-generics-and-injectables tranche hiring a Head of Specialty with complex-formulations credibility, USFDA-specialty-approval stewardship, and the specific differentiated-formulations architecture.
→Listed pharma major running USFDA remediation at a multi-plant-scale hiring a Head of Manufacturing with USFDA-remediation credibility, Schedule M / 21-CFR-Part-211 / EU-GMP compliance, and the specific data-integrity-remediation architecture.
→Listed mid-cap pharma operator scaling into specialty-and-505(b)(2) hiring a Head of Product Development with complex-and-specialty-formulations credibility and the specific 505(b)(2) regulatory-pathway stewardship.
Our Regulated Markets Formulations Track Record
Situation:
A listed large-cap pharma major with a material US-generics business and a scale-up specialty-formulations tranche needed US President succession. The brief required US-generics operating credibility, USFDA-compliance-and-wholesaler-channel stewardship, Paragraph-IV-and-first-to-file architecture fluency, and the specific multi-stakeholder architecture of running the US subsidiary within the Indian parent's governance.
Outcome:
Placed a US President with prior Head of US Generics tenure at a peer listed pharma major and subsequent President tenure at an adjacent global generics operator. Search ran 161 days across a US-and-India talent architecture. Incoming President presented a multi-year US-generics-plus-specialty plan within 75 days of joining.
Situation:
A listed pharma major running USFDA remediation across multiple plants (post a Form 483 and warning-letter cycle) needed Head of Manufacturing succession. The brief required USFDA-remediation credibility, Schedule M / 21-CFR-Part-211 / EU-GMP compliance, data-integrity-remediation stewardship, and the specific CAPA-and-investigation architecture.
Outcome:
Placed a Head of Manufacturing with prior head-of-manufacturing tenure at a peer listed pharma major (post-remediation) and subsequent VP-operations tenure at a global generics operator. Engagement included a parallel Head of Quality placement. Plants cleared their USFDA re-inspection and were cleared off warning-letter status within 18 months of the Head's joining.
Situation:
A listed pharma operator scaling its complex-generics-and-injectables tranche needed Head of Specialty succession. The brief required complex-formulations credibility (injectables, inhalation, transdermal, long-acting injectables), USFDA-specialty-approval stewardship, and the specific differentiated-formulations architecture.
Outcome:
Placed a Head of Specialty with prior head-of-complex-generics tenure at a peer listed pharma major and subsequent SVP-specialty tenure at a global generics operator. Operator announced and gained approval for multiple complex-generics-and-injectables product launches within 24 months of the Head's joining.
All client details anonymised. Specific mandates available for reference under NDA upon request.
Our Regulated Markets Formulations Practice
Formulations-regulated-markets — the US-generics, EU-generics, UK, Japan, Australia, Canada, South Africa, Brazil, and GCC formulations export business — is India's single largest pharma export tranche and one of the country's most successful global industry positions. Indian pharma operators collectively supply 40%+ of US generic-prescription volume and comparable shares in multiple EU markets. The ecosystem spans large-cap listed pharma majors with material US-generics businesses, mid-cap listed generics specialists, complex-generics and specialty-formulations specialists (listed pharma majors' specialty-and-complex-generics arms, listed biopharma-and-complex-generics operators, and India operations of global complex-generics majors), 505(b)(2) and differentiated-formulations specialists, and PE-backed export-only formulations operators. Leadership here requires fluency in USFDA, UK-MHRA, EMA, PMDA, TGA, WHO-GMP, and country-specific regulatory architecture (ANDA, DMF, CEP, MA, 505(b)(2) NDA), multi-plant regulated-markets manufacturing rhythm (Schedule M, FDA-21-CFR-Part-211, EU-GMP, PIC/S), global-customer-and-wholesaler channel architecture, complex-and-injectable-and-inhalation-and-transdermal formulation stewardship, and the specific Paragraph-IV patent-challenge and first-to-file architecture that defines US-generics economics.
We place leaders across listed pharma majors' global businesses, US-generics specialists, EU / UK / Japan / Australia generics specialists, complex-generics and specialty-formulations specialists, 505(b)(2) operators, and PE-backed export-only formulations operators. Engagements include CEO / MD searches for US subsidiaries and global businesses, President (US / North America) and Head of Europe / Head of Emerging Markets searches, Head of Regulatory Affairs (USFDA / EU) searches, Head of Manufacturing and Head of Quality searches for regulated-markets plants, Head of R&D and Head of Product Development searches, and CFO placements with regulated-markets-business and forex-management credibility. Every mandate is retained and closed-network.
As a specialist CEO mandates in global pharma, our practice also covers CTO and R&D leadership, our practice also covers Pharmaceuticals & Biotech practice overview, and as a source for Chemicals & Materials — specialty chemistry.
The Regulated Markets Formulations Landscape Today
India's pharmaceutical-formulations-export business has crossed $25-28 billion in annual revenue with the US accounting for 35-40%, EU for 15-20%, and emerging markets (South Africa, Latin America, CIS, GCC) for the balance. India is the world's largest supplier of generic drugs by volume with 40%+ share of US-generic-prescription volume. A handful of large-cap listed Indian pharma majors are the leading operators with material US-generics businesses; the largest ANDA-approval base sits with one large-cap listed integrated-generics operator; a deep Paragraph-IV first-to-file specialty sits with a listed complex-generics-positioned mid-cap. Complex-generics — injectables, inhalation products, transdermal, ophthalmic, nasal, peptides, and long-acting injectables — have emerged as the highest-margin tranche of regulated-markets formulations and where Indian operators are strategically positioning (listed pharma majors' specialty-and-complex-generics arms, listed biopharma-and-complex-generics operators, and inhalation-positioned listed Indian pharma majors). 505(b)(2) NDAs provide a differentiated-formulations pathway with improved-dosage-form or new-indication protection. The EU-generics tranche has scaled with UK-post-Brexit architecture, German-and-French-tender architecture, and Eastern Europe opportunity. Japan-generics has scaled with MHLW price-reduction-and-re-pricing architecture creating a window for Indian operators. Brazil-ANVISA, Mexico-COFEPRIS, South Africa-SAHPRA, GCC-SFDA-and-UAE-MOHAP, and Australia-TGA registrations support the emerging-markets business. The USFDA-inspection cycle — Form-483s, warning letters, import alerts, and consent decrees — remains the single largest operational risk for Indian formulations exporters. The PLI Scheme for pharmaceuticals (₹15,000 crore outlay, spanning 41 products across 3 categories) anchors capex-cycle support. Leadership in the sub-sector requires fluency in USFDA / MHRA / EMA / PMDA / TGA / WHO-GMP regulatory architecture, multi-plant regulated-markets manufacturing rhythm, global-customer-and-wholesaler channel architecture, complex-formulations stewardship, and the specific Paragraph-IV-and-first-to-file architecture. Compensation is at the upper end of Indian pharma bands.
Key Leadership Challenges in Regulated Markets Formulations
CEO / President (US / North America) placements for US-generics businesses — leaders with US-generics operating credibility, USFDA-compliance-and-wholesaler-channel stewardship, Paragraph-IV-and-first-to-file architecture fluency, and the specific multi-stakeholder architecture of running a US subsidiary within an Indian parent.
Head of Europe / Head of Emerging Markets placements — multi-geography pharma operators need Regional Heads with country-specific regulatory and commercial credibility.
Head of Regulatory Affairs (USFDA / EU) placements — regulated-markets operators need RA Heads with ANDA / DMF / CEP / MA submission credibility, remediation-and-483-response stewardship, and the specific global-regulatory-submission architecture.
Head of Manufacturing / Head of Quality placements for regulated-markets plants — multi-plant operators need Manufacturing and Quality Heads with USFDA-audit credibility, Schedule M / 21-CFR-Part-211 / EU-GMP / PIC/S compliance, and the specific remediation-and-data-integrity architecture.
Head of R&D / Head of Product Development placements — regulated-markets operators need R&D Heads with ANDA-development credibility, complex-generics stewardship, and the specific Paragraph-IV-patent-challenge-architecture.
CFO placements for listed pharma operators with material regulated-markets businesses — leaders with USFDA-inspection-risk-management credibility, forex-and-hedging stewardship, and the specific ANDA-capitalisation-and-impairment architecture.
What We Look For in Regulated Markets Formulations Leaders
Across mandates, regulated markets formulations leadership tends to cluster into a small set of archetypes. We calibrate each search against the profile your board actually needs — not the one most commonly available.
The US-Generics President
Executive who has run the US subsidiary of an Indian pharma parent or a US-generics business — fluent in US-generics operating credibility, USFDA-compliance-and-wholesaler-channel stewardship, Paragraph-IV-and-first-to-file architecture, and the specific multi-stakeholder architecture of running a US subsidiary. Often a US-domiciled executive with deep Indian-parent-interface credibility.
The Regional Head (Europe / Emerging Markets / LATAM / APAC)
Region-specialist leader with country-specific regulatory and commercial credibility, multi-country wholesaler-and-distributor stewardship, and the specific regional commercial-and-pricing architecture of the relevant region.
The Regulatory Affairs Head
Leader with ANDA / DMF / CEP / MA submission credibility, 483-and-warning-letter-remediation stewardship, global-regulatory-submission architecture fluency, and the specific post-approval-supplement and labelling-change rhythm. Often a pharmacy or chemistry graduate with subsequent Head of RA or VP-RA leadership.
The Regulated-Markets Manufacturing / Quality Head
Operations-led leader with USFDA-audit credibility, Schedule M / 21-CFR-Part-211 / EU-GMP / PIC/S compliance, multi-plant remediation-and-data-integrity stewardship, and the specific CAPA-and-investigation-architecture of regulated-markets manufacturing. Fluent in solid-oral-dosage, injectable, inhalation, and topical manufacturing.
The Regulated-Markets R&D Head
R&D leader with ANDA-development credibility, complex-generics stewardship, Paragraph-IV-patent-challenge architecture fluency, 505(b)(2) regulatory-pathway credibility, and the specific product-pipeline-and-IP architecture of regulated-markets formulations. Often a PhD-qualified formulation-scientist with subsequent Head of R&D or CTO leadership.
The Specialty / Complex-Generics Head
Segment-specialist leader with complex-formulations credibility (injectables, inhalation, transdermal, ophthalmic, nasal, peptides, long-acting injectables), USFDA-specialty-approval stewardship, and the specific differentiated-formulations architecture that separates commodity-generics from specialty-generics economics.
Regulatory & Compensation Context
Regulatory Backdrop
Formulations-regulated-markets leadership operates within the world's most dense pharmaceutical regulatory envelope. The US architecture includes USFDA (Food and Drug Administration), the Federal Food, Drug, and Cosmetic Act, 21 CFR Part 211 (cGMP), 21 CFR Part 314 (ANDA procedures), 21 CFR Part 11 (electronic records and signatures), 505(b)(2) NDA pathway, ANDA (Abbreviated New Drug Application) and DMF (Drug Master File) architecture, Paragraph-IV patent-challenge architecture under Hatch-Waxman, and the 180-day first-to-file exclusivity architecture. Form-483 observations, warning letters, import alerts, and consent decrees are the US-FDA enforcement instruments. The EU architecture includes EMA (European Medicines Agency), country-specific Competent Authorities (MHRA in UK post-Brexit, BfArM in Germany, ANSM in France, AIFA in Italy, AEMPS in Spain), the Centralised Procedure, Mutual Recognition Procedure, Decentralised Procedure, and National Procedures. EU-GMP (EudraLex Volume 4) and the PIC/S architecture govern manufacturing. EDQM CEP (Certificate of Suitability) applies for ingredient-level architecture. The UK architecture post-Brexit includes MHRA with its Great Britain authorisation and Northern Ireland architecture. The Japan architecture includes PMDA (Pharmaceuticals and Medical Devices Agency) and MHLW (Ministry of Health, Labour and Welfare) with specific JP-GMP and re-examination-and-re-evaluation architecture. The Australia architecture includes TGA (Therapeutic Goods Administration). The Canada architecture includes Health Canada. Emerging-markets registrations include ANVISA (Brazil), COFEPRIS (Mexico), SAHPRA (South Africa), SFDA (Saudi), UAE-MOHAP, and multiple country-specific registrations. WHO-GMP and WHO Prequalification apply for multilateral supply (PEPFAR, GAVI, UNICEF, Global Fund). Schedule M of the Drugs and Cosmetics Act 1940 (revised 2024, aligned with WHO-GMP) governs India-side cGMP. The Patents Act 1970, Hatch-Waxman architecture (US), SPC (Supplementary Protection Certificate) architecture (EU), and country-specific patent architecture govern IP. The Companies Act 2013 and SEBI LODR apply to listed pharma operators with specific ANDA / DMF disclosure obligations. BRSR disclosure obligations apply to listed operators. The DPDP Act 2023 applies to clinical-trial-and-PV data. Candidates for senior roles are evaluated on their USFDA-and-EMA compliance-operating history, regulatory-submission-and-remediation credibility, complex-formulations experience, and the audit-posture they have run in prior operating roles.
Compensation Architecture
Formulations-regulated-markets leadership compensation is at the upper end of Indian pharma bands with meaningful US-dollar-linked compensation architectures. Presidents / CEOs of US subsidiaries command $1.2-3.5 million total compensation (fixed $600K-1.8M plus annual bonus and meaningful LTI) — the large listed-parent-owned US businesses price at the upper band. MDs / CEOs of listed large-cap pharma majors with material regulated-markets businesses command ₹12-40 crore total compensation (covered in Formulations-Domestic entry). Heads of Europe command ₹6-15 crore fixed with multi-country business-linked variable. Heads of Emerging Markets / LATAM / APAC command ₹5-12 crore fixed. Heads of Regulatory Affairs (USFDA / EU) command ₹4-12 crore fixed — the USFDA-remediation-credibility RA Heads command the upper band. Heads of Manufacturing / Quality at regulated-markets plants command ₹4-10 crore fixed — the USFDA-remediation-experience Manufacturing Heads command the upper band. Heads of R&D / Product Development command ₹4-10 crore fixed — the complex-generics-and-505(b)(2) credibility Heads command the upper band. Heads of Specialty / Complex Generics command ₹5-12 crore fixed. CFOs of listed pharma operators command ₹5-15 crore fixed with meaningful LTI (covered in Formulations-Domestic entry). Retention architecture is the single most acute conversation in regulated-markets pharma — the competitive bid is cross-company (large-cap Indian listed pharma majors, mid-cap specialists, MNCs, complex-generics entrants) and cross-geography (US-domiciled talent often requires meaningful dollar-linked compensation architecture).
Roles We Typically Place
Why Gladwin International Leadership Advisors for Regulated Markets Formulations
CEO / President (US / North America) searches for US-generics businesses of Indian pharma majors.
Head of Europe / Head of Emerging Markets / Head of LATAM / Head of APAC placements.
Head of Regulatory Affairs (USFDA / EU / UK / Japan / Australia) and Head of Pharmacovigilance placements.
Head of Manufacturing, Head of Plant, and Head of Quality placements for regulated-markets plants.
Head of R&D, Head of Product Development, and Head of IP placements.
Head of Specialty / Head of Complex Generics / Head of Injectables / Head of Inhalation placements.
CFO and Head of IR placements with regulated-markets-business credibility.
Organisations We Serve
Listed large-cap pharma majors with material US-generics businesses
Mid-cap listed generics specialists
Complex-generics and specialty-formulations specialists (listed pharma majors' specialty-and-complex-generics arms, listed biopharma-and-complex-generics operators, and inhalation-positioned listed Indian pharma majors)
PE-backed and privately-held regulated-markets operators
US subsidiaries and European subsidiaries of Indian pharma parents
Emerging 505(b)(2) and differentiated-formulations operators
Contract-manufacturing-and-CRAMS operators serving regulated-markets customers
Regulated Markets Formulations leaders assessed on the Pharma & Biotech “HELIX” framework
Eight dimensions calibrated for pharmaceutical and biotechnology leadership. Dimensions are calibrated for regulated markets formulations mandates where relevant.
Parent Practice
Return to Pharmaceuticals & Biotechnology
Discuss a Regulated Markets Formulations Mandate
Confidential · No obligation
Response within 4 business hours · All enquiries handled by a senior practice partner · Strictly confidential